Medicinal cannabis in pharmacy: are professional attitudes changing?

With medicinal cannabis moving from the margins of healthcare debate into mainstream professional discussion, community pharmacists are encountering more patient questions. The role of pharmacy is likely to expand from gatekeeper to educator, clinical safeguard and trusted advisor.

sponsored
Medicinal cannabis products
(Shutterstock)

Since the rescheduling of cannabis-based medicinal products (CBPMs) under the UK’s Misuse of Drugs Regulations in November 2018, medicinal cannabis has moved from the margins of healthcare debate into mainstream professional discussion. What was once seen largely through the lens of criminal law or public controversy is now increasingly considered as a clinical and pharmaceutical issue. The question for pharmacy is no longer whether medicinal cannabis exists within healthcare, but how the profession should respond to it.

While caution remains, there are growing signs that attitudes among pharmacy professionals are evolving.

From scepticism to cautious engagement

When legislation changed in 2018, many pharmacists were uncertain about the role medicinal cannabis would play in UK practice. Limited prescribing routes, a lack of routine NHS access, and the fact that many products were unlicensed meant pharmacists had understandable concerns around safety, quality assurance, evidence standards and governance.

Those concerns have not disappeared. However, the conversation has become more nuanced. Increasingly, pharmacists are distinguishing between recreational cannabis and regulated CBMPs supplied under prescription controls. This shift matters. It allows medicinal cannabis to be discussed in the same way as other specialist therapies: through evidence, patient outcomes, formulation quality, risk management and professional standards.

Community pharmacists are also encountering more patient questions. As public awareness grows, patients are asking about eligibility, side effects, travel issues, interactions with other medicines and the difference between private and NHS prescribing. This increased patient demand is helping to move the subject from theory to day-to-day professional relevance.

What is driving the change?

Several factors appear to be influencing changing attitudes.

1. Greater public awareness

Media coverage, patient advocacy groups and wider discussion of chronic pain, epilepsy, anxiety and palliative care have increased awareness of medicinal cannabis. Pharmacists, as accessible healthcare professionals, are often the first point of contact when patients seek information.

2. More structured supply pathways

Although NHS prescribing remains limited, private prescribing routes have expanded significantly since 2018. That has led to the development of specialist clinics, dispensing processes and pharmacy services specifically designed for CBPMs. As supply chains become more professionalised, the sector can appear less unfamiliar to pharmacists.

3. Growing clinical interest

While evidence remains mixed depending on indication, there is increasing international research into cannabinoids for conditions such as treatment-resistant epilepsy, spasticity in multiple sclerosis, chemotherapy-induced nausea and some chronic pain settings. Pharmacists are trained to assess evidence critically, and many are now engaging with the literature rather than dismissing the category outright.

4. Professional curiosity and commercial opportunity

Independent contractors and specialist pharmacy operators are providing medicinal cannabis as a new area of service delivery. For some businesses, it offers diversification into a growing specialist medicines market.

“We first partnered with Curaleaf several years ago, initially offering the service through a small number of pharmacies in our group,” says Richard Stephenson, managing director of Right Medicine Pharmacy. “As demand has grown and the pathway has become more established, we’ve now made it available across all our pharmacies. Our part in this is very clear. We don’t make prescribing decisions. Patients are assessed independently by qualified clinicians, and they decide whether treatment is appropriate. Where a prescription is issued, our pharmacies can then dispense it.

For me, this is also about the wider role pharmacy can play in helping people access healthcare. We can signpost patients towards a regulated and legitimate route to treatment, particularly when they may not have known that route existed.

Pharmacy is often the most accessible part of healthcare, and I think we should be looking at where else we can use that position to help patients access the care and treatment they need.”

Implications for pharmacy practice

If attitudes continue to shift, medicinal cannabis could have several implications for pharmacy.

Education and training

One of the clearest needs is professional education. Many pharmacists qualified before medicinal cannabis entered legitimate UK practice and may have received little or no undergraduate teaching on cannabinoids, terpenes, dosing forms or legal frameworks. As interest grows, demand for CPD and formal training is likely to increase.

Stigma reduction

Some patients prescribed medicinal cannabis still report feeling judged or misunderstood. Pharmacists can help normalise conversations by approaching CBPMs as they would any other prescribed medicine: objectively, professionally and compassionately.

Ongoing challenges

Despite changing attitudes, medicinal cannabis is still far from routine in UK pharmacy.

Prescribing on the NHS remains limited, meaning access is often through private routes. Cost can be a barrier for patients. Regulatory scrutiny of private providers is increasing, which may ultimately strengthen standards but also raises questions about governance across the market.

The direction of travel

The profession does not appear to be moving towards uncritical acceptance of medicinal cannabis. Instead, it is moving towards something more valuable: informed pragmatism.

Pharmacists are increasingly willing to engage with medicinal cannabis as a legitimate therapeutic area while maintaining the profession’s traditional emphasis on evidence, patient safety and regulation. That measured shift could prove significant.

As demand grows and policy continues to evolve, pharmacy’s role is likely to expand from gatekeeper to educator, clinical safeguard and trusted advisor. Medicinal cannabis may still be a developing category, but it is becoming harder for the profession to ignore.

Latest from Partnered Content

More from Analysis